Recent Quotes (30 days)

You have no recent quotes
chg | %

ImmunoVaccine Inc.  

(Public, CVE:IMV)   Watch this stock  
Find more results for IMV
0.730
Delayed:   3:59PM EST
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.35 - 1.50
Open     -
Vol / Avg. 0.00/147,516.00
Mkt cap 67.59M
P/E     -
Div/yield     -
EPS -0.07
Shares 90.02M
Beta 1.17
Inst. own     -
Feb 9, 2015
Immunovaccine Inc at Biotechnology Industry Organization CEO & Investor Conference
Jan 14, 2015
Immunovaccine Inc at EBD Biotech Showcase
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -58.33% -104.66%
Return on average equity -104.41% -212.79%
Employees 20 -
CDP Score - -

Address

1344 Summer Street, Suite 412
HALIFAX, NS B3H 0A8
Canada
+1-902-4921819 (Phone)
+1-902-4920888 (Fax)

Website links

Description

Immunovaccine Inc. is a Canada-based clinical stage vaccine and immunotherapy company. The Company discovers and develops activators of the immune system to treat cancer and prevent infectious diseases. The Company�s DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The Company has advanced two T cell activation therapies for cancer through Phase I human clinical trials. The Company has research collaborations with research organizations, including the National Institutes of Health (NIH) in the United States. It has licensed the delivery technology to Zoetis, formerly the animal health division of Pfizer, Inc. for the development of vaccines for livestock.

Officers and directors

Marc Mansour Ph.D. Chief Executive Officer, Director
Age: 39
Kimberly Stephens Chief Financial Officer, Corporate Secretary
Albert James Scardino Non-Executive Chairman
Age: 65
Wade K. Dawe Director
Alfred A. Smithers Director
James W. Hall Independent Director
Age: 65
Wayne F. Pisano Independent Director